



UroGen Pharma Announces March 2020 Investor Conference Schedule

February 25, 2020

NEW YORK--(BUSINESS WIRE)--Feb. 25, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will participate in fireside chats at the following conferences in March:

Cowen and Company 40th Annual Health Care Conference

- Tuesday, March 3rd
- 11:20 AM Eastern Time
- Boston, MA

Oppenheimer 30th Annual Healthcare Conference

- Wednesday, March 18th
- 1:35 PM Eastern Time
- New York, NY

A live audio webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ with operations in New York, NY and Israel. Visit www.urogen.com to learn more or follow us on Twitter, [@UroGenPharma](https://twitter.com/UroGenPharma).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200225005069/en/>

INVESTORS:

Kate Bechtold
Senior Director, Investor Relations
Kate.Bechtold@urogen.com
914-552-0456

MEDIA:

Alice Sofield
BCW-UroGen@bcw-global.com
703-861-5654

Source: UroGen Pharma Ltd.

INVESTORS:

Kate Bechtold
Senior Director, Investor Relations
Kate.Bechtold@urogen.com
914-552-0456

MEDIA:

Alice Sofield
BCW-UroGen@bcw-global.com
703-861-5654